(People's Daily Health Client Reporters Zhao Mengmeng and Zhou Xuejin) On September 19, the Lasker Prize, an important award in the biomedical field known as the "vane" of the Nobel Prize, was announced. Among them, Joel Habener, Lotte Bjerre Knudsen, and Svetlana Mojsov won the

(People's Daily Health Client Reporter Zhao Mengmeng and Zhou Xuejin) On September 19, the Lasker Prize, an important award in the biomedical field known as the "vane" of the Nobel Prize, was announced. Among them, Joel Habener, Lotte Bjerre Knudsen, and Svetlana Mojsov won the Lasker Award for Clinical Medical Research Award, Chinese scientist Professor Chen Zhijian won the Lasker Award for Basic Medical Research, Quaraisha Abdool Karim, Salim Abdul Karim (Salim S. abdool karim ) received the lasker award for public service.

The Lasker Award is one of the most important awards in the global biomedical field. In the past 20 years alone, there have been a total of 32 Lasker Prize winners, including Chinese scientist Tu Youyou, who later won the Nobel Prize , so it is also known as the "Nobel Prize bellwether."

Lasker Award Basic Medical Research Award: Discover the cgas enzyme that senses own and foreign DNA

The 2024 Lasker Basic Research Award was awarded to Professor Chen Zhijian, a Chinese scientist and biochemist at the University of Texas Southwestern Medical Center, in recognition of his "Discovered the cgas enzyme that can sense foreign and own DNA," solved the mystery of how DNA stimulates immune and inflammatory responses, and clarified the body's process of resisting invading pathogens such as viruses, bacteria, and other microorganisms.

This enzyme can recognize free DNA produced by its own damage or the threat of foreign pathogen DNA in the cytoplasm. This provides drug targets for a variety of human diseases, and the signaling molecules it produces hold promise for fighting infectious diseases and cancer.

Chen Zhijian is one of the world's top scholars who studies innate immunity. He is also the sixth Chinese scientist to win the Lasker Award. The previous five are: Li Zhuohao (Basic Medicine Award in 1962), Li Minqiu (Clinical Medicine Award in 1972), and Jian Yuewei. (1991 Clinical Medicine Award), Tu Youyou (2011 Lasker Award for Clinical Medicine), Lu Yuming (2022 Lasker Award for Clinical Medicine).

In 2013, Chen Zhijian discovered cyclic guanylate-adenylate synthase (cgas). This enzyme is like the first domino in a chain reaction. Its activation will trigger a series of events, leading to the activation of immunity. Allow humans to respond to foreign pathogens or trigger inflammatory responses.

Regarding this study, "The Scientist" magazine in the United States, which is dedicated to life science professionals, commented: This is a key part to fill the gap in the knowledge of innate immune signaling and fully explore the role of this molecule in health and disease. , opening up exciting possibilities for tackling infections, cancer and autoimmune diseases.

The review committee also believes that this enzyme provides a drug target for a variety of human diseases, and that an in-depth understanding of this signaling pathway lays the foundation for new methods of treatment of cancer and autoimmune diseases and vaccine development.

Lasker Award for Clinical Medical Research: Discovery and development of glp-1 drugs, revolutionizing the treatment of obesity

The 2024 Lasker "Clinical Medical Research Award" was awarded to Joel Habener of Massachusetts General Hospital in the United States. ), Dr. Svetlana Mojsov from Rockefeller University in the United States, and Ms. Lotte Bjerre Knudsen from the multinational pharmaceutical company Novo Nordisk, in recognition of Their pioneering work in GLP-1 therapeutics has significantly changed the landscape of obesity treatment, providing new solutions for millions of patients around the world.

Habner and Moisov's research identified the active form of glp-1, while Ms. Knudsen translated this discovery into a clinically useful, effective weight-loss drug for people who lose weight through traditional means such as diet and exercise. Hope for obese patients who didn't make it.

"The research and development of glp-1 drugs is of epoch-making significance." On September 20, Guo Yifang, deputy chairman of the Hypertension Special Committee of the Chinese Medical Doctor Association and deputy director of Hebei Provincial People's Hospital, told the People's Daily Health Client reporter that the reason why it is said to have The epoch-making significance is that, on the one hand, it ends the history that lowering blood sugar cannot reduce macrovascular complications. In the past, although insulin, metformin and other drugs were used clinically, although they could lower blood sugar levels, they did not reduce the occurrence of cardiovascular and cerebrovascular events. However, since sglt-2 inhibitors and glp-1 receptor agonists have been on the market, treatment can lower blood sugar while reducing the risk of cardiovascular and cerebrovascular diseases.

The other aspect is weight loss. There are many kinds of weight loss drugs, but so far there are only drugs of the glp-1 class that can reduce cardiovascular complications while losing weight.

Guo Yifang said that in recent years, there have been more and more opportunities to use glp-1 clinically. Common varieties include semaglutide, liraglutide , dulaglutide, and a similar new drug called glp-1/gip dual receptor agonist tilpotide.

wrote in the commendation comments: "Nearly 900 million adults worldwide suffer from obesity, and excessive weight leads to a variety of life-threatening conditions. Obesity is often considered a failure of willpower, but for many people, Diet and exercise won't solve the problem. Historically, attempts to create safe and effective drugs to help people lose weight have led to a new era of weight management based on glp- 1 drug holds promise for significant health improvements Quaraisha Abdool Karim, , Columbia University, and Salim S. Abdool Karim, South African AIDS Research Center/Columbia University ) for elucidating the main drivers of heterosexual transmission of HIV (AIDS) and introducing methods to prevent and treat HIV.

"Elucidating the main driving factors of heterosexual sexual transmission of HIV will help to deeply understand the transmission mechanism of HIV, design prevention strategies and treatment plans, thereby reducing the spread of HIV and improving the treatment effect of patients." September 10, Beijing You'an Li Tong, chief physician of the hospital's Department of Infectious Diseases, once told the People's Daily Health Client reporter that based on these studies, corresponding preventive measures can be formulated for different groups of people, and can also provide scientific basis for governments and international organizations at the levels of public health and epidemiology.

"Abdool Karims influenced AIDS programs around the world, and they played a key role in developing science in South Africa. Throughout their careers, they championed science and its potential to benefit citizens around the world. They served under apartheid in South Africa Growing up with a deep understanding of how social inequality undermines health, education, and quality of life, they also recognize the broader implications and have practiced professional progressivism effectively in order to right the wrongs. ." read the commendation.

(People's Daily Health Client Reporter Zhao Mengmeng and Zhou Xuejin) On September 19, the Lasker Prize, an important award in the biomedical field known as the "vane" of the Nobel Prize, was announced. Among them, Joel Habener, Lotte Bjerre Knudsen, and Svetlana Mojsov won the Lasker Award for Clinical Medical Research Award, Chinese scientist Professor Chen Zhijian won the Lasker Award for Basic Medical Research, Quaraisha Abdool Karim, Salim Abdul Karim (Salim S. abdool karim ) received the lasker award for public service.

The Lasker Award is one of the most important awards in the global biomedical field. In the past 20 years alone, there have been a total of 32 Lasker Prize winners, including Chinese scientist Tu Youyou, who later won the Nobel Prize , so it is also known as the "Nobel Prize bellwether."

Lasker Award Basic Medical Research Award: Discover the cgas enzyme that senses own and foreign DNA

The 2024 Lasker Basic Research Award was awarded to Professor Chen Zhijian, a Chinese scientist and biochemist at the University of Texas Southwestern Medical Center, in recognition of his "Discovered the cgas enzyme that can sense foreign and own DNA," solved the mystery of how DNA stimulates immune and inflammatory responses, and clarified the body's process of resisting invading pathogens such as viruses, bacteria, and other microorganisms.

This enzyme can recognize free DNA produced by its own damage or the threat of foreign pathogen DNA in the cytoplasm. This provides drug targets for a variety of human diseases, and the signaling molecules it produces hold promise for fighting infectious diseases and cancer.

Chen Zhijian is one of the world's top scholars who studies innate immunity. He is also the sixth Chinese scientist to win the Lasker Award. The previous five are: Li Zhuohao (Basic Medicine Award in 1962), Li Minqiu (Clinical Medicine Award in 1972), and Jian Yuewei. (1991 Clinical Medicine Award), Tu Youyou (2011 Lasker Award for Clinical Medicine), Lu Yuming (2022 Lasker Award for Clinical Medicine).

In 2013, Chen Zhijian discovered cyclic guanylate-adenylate synthase (cgas). This enzyme is like the first domino in a chain reaction. Its activation will trigger a series of events, leading to the activation of immunity. Allow humans to respond to foreign pathogens or trigger inflammatory responses.

Regarding this study, "The Scientist" magazine in the United States, which is dedicated to life science professionals, commented: This is a key part to fill the gap in the knowledge of innate immune signaling and fully explore the role of this molecule in health and disease. , opening up exciting possibilities for tackling infections, cancer and autoimmune diseases.

The review committee also believes that this enzyme provides a drug target for a variety of human diseases, and that an in-depth understanding of this signaling pathway lays the foundation for new methods of treatment of cancer and autoimmune diseases and vaccine development.

Lasker Award for Clinical Medical Research: Discovery and development of glp-1 drugs, revolutionizing the treatment of obesity

The 2024 Lasker "Clinical Medical Research Award" was awarded to Joel Habener of Massachusetts General Hospital in the United States. ), Dr. Svetlana Mojsov from Rockefeller University in the United States, and Ms. Lotte Bjerre Knudsen from the multinational pharmaceutical company Novo Nordisk, in recognition of Their pioneering work in GLP-1 therapeutics has significantly changed the landscape of obesity treatment, providing new solutions for millions of patients around the world.

Habner and Moisov's research identified the active form of glp-1, while Ms. Knudsen translated this discovery into a clinically useful, effective weight-loss drug for people who lose weight through traditional means such as diet and exercise. Hope for obese patients who didn't make it.

"The research and development of glp-1 drugs is of epoch-making significance." On September 20, Guo Yifang, deputy chairman of the Hypertension Special Committee of the Chinese Medical Doctor Association and deputy director of Hebei Provincial People's Hospital, told the People's Daily Health Client reporter that the reason why it is said to have The epoch-making significance is that, on the one hand, it ends the history that lowering blood sugar cannot reduce macrovascular complications. In the past, although insulin, metformin and other drugs were used clinically, although they could lower blood sugar levels, they did not reduce the occurrence of cardiovascular and cerebrovascular events. However, since sglt-2 inhibitors and glp-1 receptor agonists have been on the market, treatment can lower blood sugar while reducing the risk of cardiovascular and cerebrovascular diseases.

The other aspect is weight loss. There are many kinds of weight loss drugs, but so far there are only drugs of the glp-1 class that can reduce cardiovascular complications while losing weight.

Guo Yifang said that in recent years, there have been more and more opportunities to use glp-1 clinically. Common varieties include semaglutide, liraglutide , dulaglutide, and a similar new drug called glp-1/gip dual receptor agonist tilpotide.

wrote in the commendation comments: "Nearly 900 million adults worldwide suffer from obesity, and excessive weight leads to a variety of life-threatening conditions. Obesity is often considered a failure of willpower, but for many people, Diet and exercise won't solve the problem. Historically, attempts to create safe and effective drugs to help people lose weight have led to a new era of weight management based on glp- 1 drug holds promise for significant health improvements Quaraisha Abdool Karim, , Columbia University, and Salim S. Abdool Karim, South African AIDS Research Center/Columbia University ) for elucidating the main drivers of heterosexual transmission of HIV (AIDS) and introducing methods to prevent and treat HIV.

"Elucidating the main driving factors of heterosexual sexual transmission of HIV will help to deeply understand the transmission mechanism of HIV, design prevention strategies and treatment plans, thereby reducing the spread of HIV and improving the treatment effect of patients." September 10, Beijing You'an Li Tong, chief physician of the hospital's Department of Infectious Diseases, once told the People's Daily Health Client reporter that based on these studies, corresponding preventive measures can be formulated for different groups of people, and can also provide scientific basis for governments and international organizations at the levels of public health and epidemiology.

"Abdool Karims influenced AIDS programs around the world, and they played a key role in developing science in South Africa. Throughout their careers, they championed science and its potential to benefit citizens around the world. They served under apartheid in South Africa Growing up with a deep understanding of how social inequality undermines health, education, and quality of life, they also recognize the broader implications and have practiced professional progressivism effectively in order to right the wrongs. ." read the commendation.